Several other equities research analysts also recently weighed in on the company. Morgan Stanley set a $70.00 target price on Edison International and gave the stock a hold rating in a research report on Monday, July 15th. Zacks Investment Research downgraded HEXO from a hold rating to a sell rating in a report on Wednesday, May 15th. Gabelli reissued a hold rating on shares of Endo International in a report on Wednesday, March 27th. ValuEngine downgraded Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, May 28th. Finally, Citigroup reduced their price target on Thor Industries from $78.00 to $70.00 in a report on Monday, June 17th. Four investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and three have issued a buy rating to the stock. Endo International presently has a consensus rating of Hold and a consensus price target of $10.73.
Shares of NASDAQ ENDP opened at $3.27 on Thursday. Endo International has a 1-year low of $3.21 and a 1-year high of $18.50. The stock has a 50-day moving average of $4.28. The stock has a market capitalization of $739.62 million, a P/E ratio of 1.19 and a beta of 1.15.
In other Endo International news, Director Roger H. Kimmel sold 34,951 shares of the stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $3.93, for a total transaction of $137,357.43. Following the transaction, the director now owns 148,309 shares of the company’s stock, valued at approximately $582,854.37. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 0.80% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Signition LP bought a new position in Endo International during the 1st quarter worth approximately $139,000. Factorial Partners LLC bought a new position in Endo International during the 1st quarter worth approximately $193,000. First Quadrant L P CA lifted its holdings in Endo International by 94.7% during the 1st quarter. First Quadrant L P CA now owns 24,513 shares of the company’s stock worth $197,000 after buying an additional 11,926 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in Endo International by 61.4% during the 1st quarter. Nisa Investment Advisors LLC now owns 42,256 shares of the company’s stock worth $339,000 after buying an additional 16,077 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. lifted its holdings in Endo International by 5.8% during the 1st quarter. Piedmont Investment Advisors Inc. now owns 50,737 shares of the company’s stock worth $407,000 after buying an additional 2,795 shares during the last quarter. 93.59% of the stock is currently owned by institutional investors.
Endo International Company Profile
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
See Also: How does a margin account work?
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.